Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
C4 THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 1.600 USD | -1.84% | +4.58% | -72.88% | |
| Nov. 20 | C4 Therapeutics, Inc. Appoints Owen Hughes to Its Board of Directors | CI |
| Nov. 07 | North American Morning Briefing : Higher Bond -2- | DJ |
Valuation
| Fiscal Period : December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1 426 | 1 566 | 289 | 78,8 | - | - |
| Enterprise Value (EV) 1 | 1 064 | 1 500 | 21,9 | -201 | -118 | -199 |
| P/E ratio | -21,5x | -17,7x | -2,25x | -0,63x | -0,63x | -0,56x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 42,9x | 34,2x | 9,29x | 3,66x | 3,46x | 2,95x |
| EV / Revenue | 32,1x | 32,8x | 0,70x | -9,33x | -5,19x | -7,45x |
| EV / EBITDA | -19,2x | -25,4x | -0,22x | 1,80x | 0,88x | 1,29x |
| EV / FCF | -15,7x | -17,0x | -0,20x | 1,59x | 0,81x | 1,31x |
| FCF Yield | -6,38% | -5,88% | -509% | 63,0% | 123% | 76,3% |
| Price to Book | 5,08x | 4,02x | 1,00x | 0,45x | 0,77x | 0,95x |
| Nbr of stocks (in thousands) | 43 030 | 48 626 | 48 957 | 49 281 | - | - |
| Reference price 2 | 33,1 | 32,2 | 5,90 | 1,60 | 1,60 | 1,60 |
| Announcement Date | 11/03/21 | 24/02/22 | 23/02/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period : December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 21,4 | 33,2 | 45,8 | 31,1 | 21,5 | 22,8 | 26,8 |
| EBITDA 1 | - | -55,4 | -59,1 | -97,8 | -111 | -134 | -154 |
| EBIT 1 | - | -60,4 | -82,1 | -130 | -135 | -160 | -196 |
| Operating Margin | - | -182% | -179% | -417% | -629% | -702% | -731% |
| Earnings before Tax (EBT) 1 | - | -67,0 | -83,9 | -128 | -138 | -158 | -204 |
| Net income 1 | - | -66,3 | -83,9 | -128 | -138 | -171 | -212 |
| Net margin | - | -200% | -183% | -412% | -639% | -750% | -793% |
| EPS 2 | -3,67 | -1,54 | -1,82 | -2,62 | -2,54 | -2,54 | -2,87 |
| Free Cash Flow 1 | - | -67,9 | -88,2 | -111 | -127 | -146 | -152 |
| FCF margin | - | -205% | -193% | -358% | -588% | -639% | -569% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 10.09.20 | 11.03.21 | 24.02.22 | 23.02.23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period : December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9,78 | 8,50 | 20,1 | 7,65 | 13,8 | 6,75 | 2,85 | 3,76 | 2,66 | 11,1 | 3,67 | - | - | - | - |
| EBITDA 1 | -21,6 | -23,9 | -8,58 | -31,1 | -26,9 | -32,1 | -30,9 | -35,7 | -30,7 | -27,4 | -33,9 | - | - | - | - |
| EBIT 1 | -22,1 | -24,3 | -15,3 | -31,4 | -27,4 | -32,5 | -38,3 | -36,2 | -37,6 | -27,8 | -38,4 | -47,0 | -47,0 | -53,0 | -53,0 |
| Operating Margin | -226% | -285% | -76,0% | -410% | -198% | -481% | -1 342% | -964% | -1 410% | -251% | -1 045% | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -24,7 | -15,7 | -31,6 | -27,4 | -32,0 | -37,2 | -34,8 | -35,9 | -26,0 | -39,1 | - | - | - | - |
| Net income 1 | -22,6 | -24,7 | -15,7 | -31,6 | -27,4 | -32,0 | -37,2 | -34,8 | -35,9 | -27,0 | -38,9 | -47,0 | -48,0 | -53,0 | -54,0 |
| Net margin | -231% | -290% | -78,0% | -413% | -198% | -473% | -1 303% | -925% | -1 348% | -244% | -1 058% | - | - | - | - |
| EPS 2 | -0,51 | -0,51 | -0,31 | -0,65 | -0,56 | -0,65 | -0,76 | -0,71 | -0,73 | -0,55 | -0,67 | -0,48 | -0,49 | -0,44 | -0,39 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 08/11/21 | 11/10/21 | 02/24/22 | 05/05/22 | 08/04/22 | 11/03/22 | 02/23/23 | 05/04/23 | 08/08/23 | 11/01/23 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period : December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 362 | 65,4 | 267 | 280 | 197 | 278 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -67,9 | -88,2 | -111 | -127 | -146 | -152 |
| ROE (net income / shareholders' equity) | - | - | -25,0% | -37,8% | -54,3% | -82,5% | -90,2% |
| Shareholders' equity 1 | - | - | 335 | 339 | 253 | 207 | 236 |
| ROA (Net income/ Total Assets) | - | - | -18,5% | -27,3% | -40,2% | -90,6% | -114% |
| Assets 1 | - | - | 453 | 469 | 343 | 188 | 186 |
| Book Value Per Share 2 | - | 6,52 | 8,00 | 5,92 | 3,53 | 2,08 | 1,68 |
| Cash Flow per Share 2 | - | - | -1,89 | -2,17 | -2,41 | -3,32 | -6,14 |
| Capex 1 | - | 0,65 | 1,28 | 5,50 | 4,50 | 4,45 | 5,52 |
| Capex / Sales | - | 1,96% | 2,79% | 17,7% | 20,9% | 19,6% | 20,6% |
| Announcement Date | 09/10/20 | 03/11/21 | 02/24/22 | 02/23/23 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
1.600USD
Average target price
16.20USD
Spread / Average Target
+912.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -72.88% | 79 M $ | |
| +65.53% | 40 132 M $ | |
| +5.87% | 39 586 M $ | |
| -55.56% | 30 438 M $ | |
| -26.11% | 28 571 M $ | |
| +38.66% | 22 175 M $ | |
| -27.87% | 21 511 M $ | |
| +1.62% | 17 412 M $ | |
| -13.43% | 11 313 M $ | |
| -7.44% | 10 346 M $ |
- Stock
- Equities
- Stock C4 Therapeutics, Inc. - Nasdaq
- Financials C4 Therapeutics, Inc.
